Torrent Pharma Q3 Results Review - Branded Generics, The U.S. Led Earnings Growth Revival: Motilal Oswal
Even the rest of world market witnessed strong growth during the quarter.
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Torrent Pharmaceuticals Ltd. delivered in-line Q3 FY23 earnings, fueled by robust performance in the branded generics segment of domestic formulation/Latin America as well as the U.S. generics segment. Even the rest of world market witnessed strong growth during the quarter.
We raise our earnings per share estimates for Torrent Pharma by 1.0%/3.0%/3.7% for FY23/FY24/FY25 to factor in:
new launches as well as market share gains in existing launches in LatAm, and
better scope of price-led growth in DF.
We estimate 19%/26% Ebitda/earnings compound annual growth rate over FY23-25, respectively, led by superior execution in branded generics segment and gradual uptick in tender wins in Germany.
The return ratios remained suppressed due to regulatory hurdles at Indrad and Dahej for the U.S. market. Besides, the valuation adequately factors in earnings upside over FY23-25E.
Click on the attachment to read the full report:
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.